Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy-Reference-Cited by-同舟云学术

Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy

Published:2018-01-11 Issue:3 Volume:23 Page:559-567
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Ishihara Hiroki^ORCID,Takagi Toshio,Kondo Tsunenori,Tachibana Hidekazu,Yoshida Kazuhiko,Omae Kenji,Iizuka Junpei,Kobayashi Hirohito,Tanabe Kazunari

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/article/10.1007/s10147-018-1241-3/fulltext.html

Reference21 articles.

1. Figlin R, Sternberg C, Wood CG (2012) Novel agents and approaches for advanced renal cell carcinoma. J Urol 188:707–715

2. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

3. Duran I, Lambea J, Maroto P et al (2017) Resistance to targeted therapies in renal cancer: the importance of changing the mechanism of action. Target Oncol 12:19–35

4. Seidel C, Busch J, Weikert S et al (2012) Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Eur J Cancer (Oxford, England: 1990) 48:1023–1030

5. Wells JC, Stukalin I, Norton C et al (2017) Third-line targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 71:204–209

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update;Journal of Cancer Research and Clinical Oncology;2024-04-09

2. Advances in Renal Cell Carcinoma Drug Resistance Models;Frontiers in Oncology;2022-05-10

3. Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era;Targeted Oncology;2022-04-23

4. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data;Japanese Journal of Clinical Oncology;2020-12-15

5. Efficacy of nivolumab versus molecular‐targeted therapy as second‐line therapy for metastatic renal cell carcinoma: Real‐world data from two Japanese institutions;International Journal of Urology;2020-11-06